Drug Trial Radar · NCT06457919
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jun 4, 2024
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- TransThera Sciences
- First posted
- Jun 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).
Conditions
- Prostate Cancer
Interventions
TinengotinibDrug
Tinengotinib will be administered daily for 28-day cycles. A flat dose of 10 mg PO once daily.
abiraterone acetate with prednisoneDrug
Abiraterone acetate 1000 mg PO QD in combination with prednisone 5 mg PO once or twice daily (QD or BID)
EnzalutamideDrug
Enzalutamide 160 mg PO QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- RP2DTime frame: From the start of study treatment through the DLT window (28 days)
- Objective Response Rate (ORR)Time frame: up to 6months
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Yale University (Data Collection Only)
New Haven, Connecticut · Recruiting
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey · Recruiting
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey · Recruiting
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey · Recruiting
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
Commack, New York · Recruiting
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York · Recruiting
Columbia University
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York · Recruiting
Duke University
Durham, North Carolina · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.